11/2/2011

The FDA has granted Abbott Laboratories approval for its XIENCE PRIME everolimus-eluting stent for use in treating patients with coronary artery disease. The device has an improved design that allows more flexibility and accuracy in stent delivery and placement.

Full Story:
Reuters

Related Summaries